Mobile Downtown Redevelopment Authority Bonds Series 2011A Rating Lowered To 'AA-/A-1+' Dec 11

  • ID: 2034045
  • December 2011
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Dec. 16, 2011--Standard & Poor's Ratings Services today lowered its rating on Mobile Downtown Redevelopment Authority's gulf opportunity zone revenue bonds series 2011A (for the Austal USA LLC project) due May 1, 2041, to 'AA-/A-1+' from 'AA/A-1+'. Our rating on the series 2011A bonds reflects our opinion of the credit and liquidity support that National Australia Bank Ltd. ('AA-/Stable/A-1+') provides in the form of an irrevocable direct-pay letter of credit (LOC). The long-term component of our rating is based on our long-term issuer credit rating on National Australia Bank Ltd. and addresses the full and timely payment of interest and principal when the bondholders have not exercised the put option. The short-term component of our...

Companies mentioned in this report are: Mobile Downtown Redevelopment Authority (The)
Action: Downgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Mobile Downtown Redevelopment Authority (The)

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.